Dr Robert S Schmidli

MB ChB, FRACP, MRCP, PhD

Publications

Thesis

  1. Glutamic Acid Dearboxylase Immunity and Regulation In IDDM (PhD)

Original papers

  1. Schmidli RS, Donald RA, Espiner EA.  ACTH deficiency - problems in recognition and diagnosis.  NZ Med J 1989; 102: 255-257.
  2. Schmidli RS, Wilson I, Espiner EA, Richards AM, Donald RA.  Aminohydroxypropylidine diphosphonate (APD) in primary hyperparathyroidism; effect on clinical status.  Clin Endocrinol 1990; 32: 293-300.
  3. Ellis MJ, Schmidli RS, Donald RA, Livesey JH, Espiner EA.  Plasma corticotrophin-releasing factor and vasopressin responses to hypoglycaemia in normal man.  Clin Endocrinol 1990; 32: 93-100.
  4. Schmidli RS, Lynn KL.  Acute renal failure complicating non-fulminating hepatitis A infection - a case report.  NZ Med J 1990; 103: 375.
  5. Schmidli RS, Scott RS, Bremer JM, Shand BI, Elliott T, Moore MP.  Effect of supplementary night-time insulin on rheology and atherogenic risk factors in type 2 diabetes mellitus.  Cardiovasc Risk Factors 1991; 1: 361-367.
  6. Schmidli RS, Hagan C, Scott RS, Livesey J, Forbes LV.  Plasma proinsulin in recently diagnosed type 2 diabetes mellitus.  Diab Res Clin Pract 1993; 20: 133-138.
  7. Harrison LC, Honeyman MC, DeAizpurua HJ, Schmidli RS, Colman PG, Tait BD, Cram DS.  Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes.  Lancet 1993; 341: 1365-1369.
  8. Schmidli RS, DeAizpurua HJ, Harrison LC, Colman PG.  Antibodies to glutamic acid decarboxylase in at-risk and clinical insulin-dependent diabetic subjects: relationship to age, sex and islet cell antibody status, and temporal profile.  J Autoimmunity 1994; 7: 55-66.
  9. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC.  High level of concordance between assays for glutamic acid decarboxylase antibodies (GADAb): the first international GADAb workshop. Diabetes 1994; 43: 1005-1009.
  10. Schmidli RS, Colman PG, Harrison LC.  Do glutamic acid decarboxylase antibodies improve the prediction of IDDM in first-degree relatives at-risk for IDDM?  J Autoimmun 1994; 7: 873-879.
  11. Schmidli RS, Colman PG, Bonifacio E.  Disease sensitivity and specificity of fifty-two assays for glutamic acid decarboxylase antibodies: the second international glutamic acid decarboxylase antibody workshop.  Diabetes 1995; 44: 636-640.
  12. Schmidli RS, Faulkner-Jones BE, James RFL, Harrison LC, DeAizpurua HJ.  Cytokine regulation of GAD biosynthesis in isolated rat islets of Langerhans.  Biochem J 1996; 317: 713-9.
  13. Willis JA, Scott RS, Brown LJ, Forbes LV, Schmidli RS, Zimmet PZ, Mackay IR, Rowley MJ.  Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus.  Diab Res Clin Pract 1996; 33: 89-97.
  14. Cui L, Yu W-P, DeAizpurua HJ, Schmidli RS, Pallen CJ.  Cloning and characterization of IAR, a novel receptor-like protein tyrosine phosphatase and autoantigen in insulin-dependent diabetes.  J Biol Chem 1996; 271: 24817-24823.
  15. Schmidli RS, Colman PG, Cui L, Yu W-P, Kewming K, Jankulovski C, Harrison LC, Pallen CJ, DeAizpurua HJ.  Antibodies to the novel protein tyrosine phosphatase IAR predict development of insulin-dependent diabetes (IDDM) in first-degree relatives at-risk for IDDM.  Autoimmunity.  1998; 28: 15-23.
  16. Colman PG, McNair P, Margetts H, Schmidli RS, Werther G, Alford F, Ward GM, Tait BD, Honeyman MC, Harrison LC.  The Melbourne prediabetes study: prediction of type 1 diabetes mellitus using antibody and metabolic testing.  Med J Aust 1998; 169: 81-4.
  17. Colman PG, McNair PD, Gellert S, Kewming K, Schmidli RS, Steele CE, Harrison LC.  Development of autoantibodies to islet antigens during childhood: implications for preclinical type 1 diabetes screening. Pediatr Diabetes 2002; 3:144-8.
  18. Vress D, Schmidli RS. Evaluation of transition of type 1 diabetes paediatric patients to the adult service at the Canberra Hospital. MSJA 2011; 3: 18-23.
  19. Somi N, Schmidli RS. Prospective study of the effect of Subcutaneous Insulin Infusion on the quality of life of patients with type 1 diabetes mellitus. MSJA 2013; 5: 6-9.
  20. Okolie K, Chen D, Ghabrial R, Schmidli RS. Exophthalmos and multinodular goitre, an unusual combination. Endocrinol Diabetes Metab Case Rep. 2019; 2019: 18-0138.
  21. Huajing N, Schmidli RS, Savkovic S, Strasser SI, Hetherington J, Cooper B, Desai R, Handelsman DJ. Depot Pure GnRH Antagonist for Long-term Treatment of Ovarian Hyperthecosis Monitored by Multi-Steroid LCMS Profiling. JES (in press)
  22. 22. Parkinson A, Brew-Sam N, Hall Dykgraaf S, Nolan C, Lafferty A, Schmidli R et al. Managing type 1 diabetes during the COVID-19 pandemic is a team effort: a qualitative study of the experiences of young people and their parents. Integ Health J 2021;3:e000082

Chapters, reviews

  1. Harrison LC, Schmidli RS, Petrovsky N, Honeyman MC.  Insulin-dependent diabetes.  In: Clinical Immunology.  Oxford University Press.  (Bradley J, McClusky J eds.).
  2. Schmidli RS, Harrison LC.  GAD Antibodies.  In: Textbook of autoantibodies.  (Shoenfeld Y, Peter JB eds.).
  3. Faulkner-Jones BE, French M, Schmidli RS, Williamson S, Cram DS, Honeyman MC, Harrison LC.  Expression and function of glutamic acid decarboxylase (GAD) as an autoantigen in insulin-dependent diabetes.  In: Lessons from Animal Diabetes. (Shafrir E ed.).
  4. Schmidli R, Lafferty KJ.  Diabetes: of mice and men.  Today's Life Science 1998; 10: 20-24.
  5. Schmidli RS. PCSK9 inhibitors: clinical applications. Aust Prescr 2016;39:168-701 DOI: 10.18773/austprescr.2016.061

Formal presentations

Appointments